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AbstrACt
Introduction With almost 50% of cases preventable and 
the Australian National Bowel Cancer Screening Program 
in place, colorectal cancer (CRC) is a prime candidate for 
investment to reduce the cancer burden. The challenge 
is determining effective ways to reduce morbidity and 
mortality and their implementation through policy and 
practice. Pathways- Bowel is a multistage programme 
that aims to identify best- value investment in CRC 
control by integrating expert and end- user engagement; 
relevant evidence; modelled interventions to guide 
future investment; and policy- driven implementation of 
interventions using evidence- based methods.
Methods and analysis Pathways- Bowel is an iterative 
work programme incorporating a calibrated and validated 
CRC natural history model for Australia (Policy1- Bowel) 
and assessing the health and cost outcomes and resource 
use of targeted interventions. Experts help identify and 
prioritise modelled evaluations of changing trends and 
interventions and critically assess results to advise on 
their real- world applicability. Where appropriate the 
results are used to support public policy change and make 
the case for optimal investment in specific CRC control 
interventions. Fourteen high- priority evaluations have 
been modelled or planned, including evaluations of CRC 
outcomes from the changing prevalence of modifiable 
exposures, including smoking and body fatness; potential 
benefits of daily aspirin intake as chemoprevention; 
increasing CRC incidence in people aged <50 years; 
increasing screening participation in the general and 
Aboriginal and Torres Strait Islander populations; 
alternative screening technologies and modalities; and 
changes to follow- up surveillance protocols. Pathways- 
Bowel is a unique, comprehensive approach to evaluating 
CRC control; no prior body of work has assessed the 
relative benefits of a variety of interventions across CRC 
development and progression to produce a list of best- 
value investments.
Ethics and dissemination Ethics approval was not 
required as human participants were not involved. Findings 
are reported in a series of papers in peer- reviewed 
journals and presented at fora to engage the community 
and policymakers.
IntroduCtIon
background
Colorectal cancer (CRC) was the third most 
commonly diagnosed cancer in Australia in 
2017, with estimated incidence of 63.4 per 
100 000 and 45.8 per 100 000 in men and 
strengths and limitations of this study
 ► Pathways- Bowel leverages a fully calibrated natural 
history microsimulation model for colorectal cancer 
(CRC) (Policy1- Bowel) to model evaluations of ex-
isting and hypothetical trends and interventions to 
improve CRC outcomes for Australians.
 ► It aims to bridge the gap between end- user pri-
orities, epidemiological and statistical research 
outputs, and practical applicability from health, re-
source and health system cost perspectives.
 ► Findings from the Pathways- Bowel programme are 
applicable to Australia; however, the flexibility of 
Policy1- Bowel enables its future adaptation to other 
settings where location- specific data are available.
 ► The predictive modelling used is limited by and de-
pendent on the available data sources and assump-
tions made when empirical data are absent.
 ► The overarching Pathways programme generates 
evidence on the best- value investments or ‘best 
buys’ in cancer control across multiple cancers to 
inform future decision making.
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women, respectively.1 2 A small proportion of CRC cases 
are found in higher- risk patients and associated with 
strong family history of CRC or hereditary syndromes. 
Lynch syndrome and familial adenomatous polyposis 
account for ~3% and less than 1% of new CRC cases, 
respectively.3–5 The Australian Burden of Disease Study 
found there were over 95 000 years of healthy life lost 
due to CRC in 2015, which accounted for 2% of the total 
disease burden in Australia.6 From 1982 to 2015, CRC 
incidence and mortality rates decreased (from 58.3 to 
57.4 and from 32.3 to 19.2 per 100 000, respectively),7 
with noted gender, socioeconomic and geographical 
disparities in these reductions.8–11 The 5- year overall 
survival from CRC in Australia increased from 51% in 
1985–1989 to 70% in 2010–2014.12 A recent analysis high-
lighted increasing CRC incidence in people under 50 
years of age, which could be partially attributable to the 
rising prevalence of harmful risk factors, but there are, as 
yet, no confirmed causes.13 Nearly half (49.8%) of new 
CRC cases in Australia are attributable to known modifi-
able risk factors14 and therefore could be influenced by 
primary prevention interventions. Evidence on policies 
and interventions for preventing CRC through lifestyle 
change varies widely between risk factors. On current 
evidence, the best buy in CRC control is increasing partic-
ipation in Australia’s National Bowel Cancer Screening 
Program (NBCSP)15; however, fewer than half the eligible 
population are participating. From 2020, all Austra-
lians aged 50–74 will be invited to participate in bien-
nial screening using an immunochemical faecal occult 
blood test (iFOBT).12 Further decreases in incidence and 
mortality of 23% and 36%, respectively, are anticipated by 
2040 at current participation rates with full implementa-
tion of the NBCSP.15
Pathways
‘Pathways to a cancer- free future’ (‘Pathways’) is a programme 
of research developed to focus investment where the 
biggest impact can be made at a population level. It aims 
to identify the best- value investments, or ‘best buys’, in 
cancer control to inform future decision making. First 
described in relation to cervical cancer,16 the Pathways 
model is now being applied to five major cancers—
cervical, lung, colorectal, prostate and breast cancer—and 
to cancers relating to Lynch syndrome, and early work has 
commenced in melanoma and cancers of the ovary and 
liver. Pathways- Bowel refers to the programme focused on 
CRC, with a detailed assessment of high- risk individuals 
with Lynch syndrome and other Lynch- related cancers 
incorporating evidence- based intervention implementa-
tion currently under way,17 18 as part of Pathways- Lynch. 
Pathways- Bowel will span the CRC control continuum 
from primary prevention to survivorship. It aims to model 
comparative evaluations of CRC interventions guided by 
the best available evidence to underpin future research 
investment and policy implementation. The aim of the 
current article is to outline the design and objectives of 
Pathways-Bowel. Pathways- Bowel will inform ongoing and 
planned modelled evaluations of CRC interventions by 
integrating expert and end- user engagement; relevant 
evidence; modelled interventions to guide future invest-
ment; and policy- driven implementation of interventions 
using evidence- based methods.
MEthods And AnAlysIs
study design
Pathways as an overarching programme was previously 
described.16 Since that time, Pathways has changed from a 
staged approach to a more iterative process. As modelled 
evaluation results become available, they are immediately 
reviewed and disseminated as appropriate to support 
potential policy change.
Patient and public involvement statement
Multisectoral stakeholder involvement in Pathways- 
Bowel is achieved via a multidisciplinary Scientific Advi-
sory Committee (SAC) including academics, clinicians, 
consumers and advisers on policy. The SAC is designed 
to ensure involvement from relevant stakeholders outside 
the core research team and confirm the relevance of 
modelled evaluations and their translation. The SAC was 
first convened to discuss CRC in March 2018. Since then, 
members continue to be consulted based on their area of 
expertise to guide, critique and support the programme 
and its recommendations, thus ensuring there is involve-
ment from interested parties throughout the process.
Processes and analysis for modelled evaluations of 
interventions
Modelling platform: Policy1-Bowel
We use a previously developed microsimulation model 
platform, Policy-1 Bowel, to perform predictive modelled 
evaluations of CRC interventions in Australia.19 Policy1- 
Bowel is a comprehensive platform that synthesises clin-
ical, epidemiological, demographic, behavioural and 
economic data and has been used to simulate the impact 
of CRC screening in Australia.15 Existing Policy1- Bowel 
evaluations have assessed a range of screening scenarios 
and provided estimates of CRC outcomes, resource util-
isation and costs. They have, for example, analysed the 
use of various CRC screening test technologies and target 
age ranges for the NBCSP to inform Australian guide-
lines.20 21 The model platform is implemented in C++ and 
includes several interconnected elements to evaluate the 
NBCSP. It incorporates the development of CRC from 
adenoma (via the adenoma- carcinoma pathway) and 
sessile serrated lesions (via the serrated pathways) and 
survival from CRC (see figure 1). Policy1- Bowel then incor-
porates screening for average- risk people, including post-
screening diagnosis, treatment and surveillance (figure 2 
summarises the current NBCSP screening delivery path-
ways included). As evaluations are conducted, single- 
cohort or multiple- cohort approaches are used to 
simulate the development of polyps and CRC, screening, 
diagnosis and other downstream NBCSP processes in 
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Figure 1 Schematic diagram of the Policy1- Bowel 
microsimulation model platform. *Cancer patients surviving 
five years after diagnosis and treatment become cancer 
survivors. Cancer survivors in the model were assumed to 
have no additional risk of death due to colorectal cancer 
compared with the average population with no colorectal 
cancer. CRC, colorectal cancer; HG, high grade; LG, low 
grade.
Figure 2 Screening delivery pathway (based on NBCSP) 
modelled in the Policy1- Bowel microsimulation model 
platform. #Including people who were not recommended 
to attend colonoscopy due to coexistent disease or other 
health issues and people who did not comply with GP’s 
colonoscopy referral. *Barclay, K. Cancer Council Australia 
Surveillance Colonoscopy Guidelines Working Party. 
Algorithm for colonoscopic surveillance intervals–adenomas, 
2013. Available at: http://www.gastroservices.com.au/pdf/
algorithm-for-colonoscopic-surveillance-intervals-adenomas.
pdf (accessed 28 December 2016). AA, advanced adenoma; 
GP, general practitioner; iFOBT, immunochemical faecal 
occult blood test; NBCSP, National Bowel Cancer Screening 
Program; SSL, sessile serrated lesion.
the target population over a time period of interest. The 
resulting evaluation is informed by Australian- specific 
demographic data and economic and health utilities 
data obtained from national and international literature 
(including cost and quality- adjusted life years) to produce 
cross- sectional results for the population. For modelled 
evaluations of CRC interventions, data are sourced from 
national surveys and data collection agencies (eg, Austra-
lian Institute of Health and Welfare: AIHW) and the 
published literature including meta- analyses, systematic 
reviews, randomised controlled trials, cohort studies and 
other relevant publications. Where empirical data are 
not available, the SAC and other experts are consulted to 
guide the assumptions used.
Policy1-Bowel validation
Extensive calibration of the model has been carried 
out against a wide range of current NBCSP outputs and 
other Australian data sources.15 The model has also been 
validated against the findings of other well- established 
microsimulation models and multiple large randomised 
controlled trials with long- term follow- up. Further details 
of the model used in this work, and descriptions of its 
development, parameterisation, data sources, calibration 
and validation outcomes, have been published previously 
and technical appendices are available.15 19–21
Economic analysis
The modelled evaluations result in economic analyses to 
develop a business case for investment. Pathways- Bowel 
(and all Pathways) uses a common framework so the best- 
value investment, or ‘best buy’, can be compared within 
and between analyses. This framework is in development 
and will be based on similar initiatives internationally.22 
The populations of interest are average- risk Australians 
and subgroups relevant to the modelled evaluations. For 
each evaluation, several primary outcomes are consid-
ered, including the following:
 ► Health benefits, for example, reduction in lifetime 
risk of CRC incidence and mortality.
 ► Harms, for example, hospitalisations and adverse 
events of colonoscopy.
 ► Resource use, for example, health costs of CRC 
(hospitals, workforce, screening and diagnostic tests, 
programme communications and so on).
 ► Health economic outcomes, for example, discounted 
and undiscounted lifetime cost, life years, quality- 
adjusted life years, disability- adjusted life years and 
cost- effectiveness.
For each intervention, the primary outcomes listed 
may be expanded or differ. The comparator for analyses 
is the general population or specific subgroup of interest 
without the influence of the intervention being assessed. 
The potential harms associated with interventions are 
often minimal, but Pathways will enable their characterisa-
tion and quantification. For example, the health benefits 
and harms for screening would also include colonoscopy- 
related adverse events and number needed to colonos-
cope per CRC death prevented.
A health services perspective is applied, and efforts 
are being made to expand to the societal perspective, 
including characterisation of out- of- pocket expenses. 
From a health services perspective, costs incurred by 
governments and the health system over a person’s life-
time are incorporated. For each evaluation, multiple time 
horizons may be chosen as appropriate to the specific 
intervention, but the common time horizon is to 2050 (as 
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Table 1 Priority modelled evaluations for CRC interventions
Evaluation Focus area Status
Impact* of changing smoking prevalence on CRC. Reducing risk of CRC. Ongoing.
Impact* of changing body fatness prevalence and 
distribution on CRC.
Reducing risk of CRC. Ongoing.
Impact* of daily aspirin prophylaxis on CRC. Reducing risk of CRC. Ongoing.
Impact* of NBCSP in the long term due to the increasing 
CRC incidence in younger cohorts.
NBCSP outcomes: changing temporal 
trends.
Ongoing.
Impact* of extending the NBCSP to younger ages for birth 
cohorts with increasing CRC rate.
NBCSP outcomes: changing temporal 
trends.
Ongoing.
Impact* of extending the NBCSP to people aged 40–49 
years for the Aboriginal and Torres Strait Islander peoples.
NBCSP outcomes: targeting population 
subgroups with different CRC risk profiles.
Complete.
Impact* of extending the NBCSP to younger (40–49 years) 
and/or older (75–84 years) ages of average- risk Australians.
NBCSP outcomes: targeting NBCSP 
participation to a broader age range.
Published.
Impact* of the NBCSP at currently observed rates in the 
long term.
NBCSP outcomes: long- term NBCSP 
participation.
Published.
Impact* of increasing NBCSP participation to 60% and 
70%.
NBCSP outcomes: increasing NBCSP 
participation rates.
Published.
Impact* of optimising NBCSP adherence (iFOBT screening 
and diagnostic assessment) to 90% and quantifying a 
threshold for cost- effective investment towards improving 
NBCSP adherence.
NBCSP outcomes: increasing NBCSP 
participation rates.
Published.
Impact* of mass media campaigns aimed at increasing 
participation in NBCSP.
NBCSP outcomes: increasing NBCSP 
participation rates.
Published.
Impact* of including twice- off screening colonoscopies at 
ages 40 and 60 in addition to the current NBCSP.
NBCSP outcomes: alternative screening 
methods.
Published.
Impact* of 13 alternative screening approaches involving use 
of iFOBT, colonoscopy, sigmoidoscopy, CT colonography, 
faecal DNA and plasma DNA for the NBCSP.
NBCSP outcomes: alternative screening 
methods.
Published.
Impact* of modifications to colonoscopic surveillance 
protocols, especially the newly ratified Australian 
colonoscopy surveillance guidelines to the previous 
guidelines.
NBCSP outcomes: modifying colonoscopic 
surveillance management.
Ongoing.
*The impact of listed evaluations assessed in terms of health outcomes, resource use and costs.
CRC, colorectal cancer; iFOBT, immunochemical faecal occult blood test; NBCSP, National Bowel Cancer Screening Program.
this timeline indicates a change within a generation). In 
terms of an indicative willingness- to- pay (WTP) threshold, 
$30 000–$50 000 per life year saved has previously been 
used for evaluations of interventions for CRC and cervical 
cancer.20 23 24 In Pathways, a 5% annual discount rate and 
the indicative WTP threshold of $30 000–$50 000 per 
life year saved are used, with alternative WTP thresholds 
included for comparability. Our focus is to quantify and 
compare cost- effectiveness in all our analyses. One- way 
and probabilistic sensitivity analyses and uncertainty anal-
yses will be conducted as required to assess the impact 
of model parameter uncertainties on the key model 
findings.
Rationale for modelled evaluations of CRC interventions
Under the guidance of the SAC, a list of priority modelled 
evaluations for CRC interventions was compiled. Evalu-
ations are preceded by exploratory scoping reviews of 
the literature to identify potential interventions, and are 
escalated to a full systematic review to source evidence 
for predictive modelling as required and determined by 
the SAC. The ongoing and planned interventions are 
listed in table 1 and represent the first series of evalua-
tions. Broadly, these evaluations cover interventions to 
reduce CRC risk, interventions in light of changing inci-
dence trends, modifications to the NBCSP via target age 
groups, increased participation and alternative screening 
methods, and improved surveillance management. Find-
ings have and will continue to be reviewed by the SAC as 
required. At a later date, these evaluations will grow and 
could include topics of growing public interest, such as 
the promotion of healthy diet, and extend to later stages 
of CRC control as evidence becomes available.
While Policy1- Bowel has been used to evaluate the 
NBCSP, it is a flexible and dynamic model which can be 
adapted to incorporate both alternative screening inter-
ventions as well as interventions addressing other stages of 
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the CRC continuum. Policy1- Bowel proves a critical tool for 
assessing the ‘best buys’ for CRC. The following section 
outlines how Pathways- Bowel is being used in the contexts 
of primary prevention, screening and early detection and 
treatment for CRC.
Primary prevention: reducing risk
Promoting healthy behaviours and reducing risk through 
primary prevention can play an important role in CRC 
control.14 Targeted primary prevention interventions to 
reduce CRC risk could address any or all of the following: 
tobacco use, alcohol use, body fatness, insufficient phys-
ical activity, insufficient dietary fibre intake, and excess red 
and processed meat intake.25–27 Except for tobacco use, 
the prevalence of these risk factors has increased in Austra-
lians in recent decades, and for some key risk factors, such 
as body fatness, prevalence in children is rising and calls 
for action are increasing.28 The 2017 Australian clinical 
practice guidelines for CRC recommend low- dose daily 
aspirin use for all people aged 50–70, as evidence suggests 
its potential effectiveness in CRC primary prevention.29 30 
More recent studies have begun exploring the role of 
the gut microbiota in the development of CRC, which 
can be indirectly affected by diet.31 In practice, evidence- 
based interventions addressing these risk factors are chal-
lenging to comprehensively evaluate without information 
on medium- term to long- term CRC outcomes. Pathways- 
Bowel will synthesise the available evidence from national 
and international data sources and published evidence to 
estimate the likely impact on CRC outcomes in the future 
for modelled evaluations. Initially, the priorities in this 
area (table 1) are (1) changing smoking prevalence; (2) 
changing body fatness prevalence and distribution; and 
(3) impact of daily aspirin prophylaxis. Other behaviours, 
such as alcohol consumption and diet, may be added at 
a later stage.
screening and early detection: nbCsP outcomes
Identification and removal of precancerous adenomas can 
prevent CRC development, and early detection of malig-
nancies improves survival. The technology for these inter-
ventions is effective, available, affordable and acceptable, 
making CRC an ideal candidate for an organised popu-
lation screening programme.32 The NBCSP participation 
rate over the 2016–2017 period was about 40% nation-
ally.12 Current reported rates of colonoscopy for assess-
ment of individuals with a positive NBCSP- iFOBT test 
are approximately 66%, with known under- reporting.12 
Recommended screening for people at intermediate or 
high CRC risk due to family history of CRC or heredi-
tary syndromes is more intense, beginning at a younger 
age, and may include iFOBT and colonoscopy screening 
depending on level of risk, informed by evidence.33 In 
addition, ongoing surveillance of individuals with either a 
positive iFOBT or polyps removed at colonoscopy follows 
varying management recommendations based on indi-
vidual risk and colonoscopy results.34
National reports issued by the AIHW, along with other 
studies, have drawn attention to NBCSP participation 
disparities by gender, geographical location, Indigenous 
status, place of birth and language spoken at home.12 35–37 
Interventions to promote CRC screening that are used 
revolve largely around general population awareness 
and health organisation or practitioner endorsement of 
participation and follow- up.38–40 Efforts are now being 
made by government and not- for- profit organisations to 
improve NBCSP participation.41–43 Such interventions 
are likely to be cost- effective investments.41 42 Evaluations 
of interventions to support compliance with recommen-
dations for screening, follow- up and surveillance and to 
assess the best use of existing health resources could also 
be conducted, when data on the performance of these 
interventions are available.
Australia has a national organised, federally funded 
screening programme that began in 2006. It has under-
gone phased roll- out, nearing full implementation, and 
should be taken into account in any modelled evaluation. 
The Pathways- Bowel priority areas cover predictive model-
ling of the NBCSP outcomes under a range of conditions 
or changes in the external environment or programme 
(table 1). These scenarios are (1) changing temporal inci-
dence trends; (2) targeting NBCSP participation in popu-
lation subgroups; (3) targeting NBCSP participation to a 
broader age range; (4) long- term NBCSP participation at 
varying rates; (5) NBCSP participation increased by simu-
lated mass media campaigns; (6) using alternative tech-
nologies; and (7) modifying surveillance management.
treatment
Once diagnosed, surgery is generally considered as initial 
treatment, with or without adjuvant chemotherapy or 
radiation therapy.44 45 The goal of surgery is to remove 
any tumour as well as surrounding tissue either laparo-
scopically or via traditional open surgery.46 Variations in 
treatment pathways more often relate to adjuvant chemo-
therapy where there are differences in guidelines and 
outcomes based on stage, location and genetic mutations. 
Metastatic disease is treated with systemic chemotherapy 
and biological therapies. Bevacizumab, added to the 
Pharmaceutical Benefit Schedule (PBS) for Australian 
Government subsidies in 2009, can be used in addition 
to chemotherapy in metastatic CRC cases and has been 
found to prolong both progression- free survival (from 
7.1 to 9.7 months) and overall survival (from 17.7 to 20.5 
months) in first- line and second- line therapy.47 Cetux-
imab and panitumumab are also PBS- subsidised for use 
in patients with rat sarcoma viral oncogene homologue 
(RAS) wild- type CRC.48 Besides these, there have been 
few modifications to the PBS related directly to CRC ther-
apies. Immunotherapy has proven effective in early and 
advanced microsatellite unstable CRC tumours, which 
can comprise 15% of all CRC or more for those under 
50 years.49 Research continues in this area with an active 
interest in the concept of personalised medicine with ther-
apies for specific CRC subtypes, including the possible use 
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of organoids to predict therapy response.49 50 There have 
been calls for further research into several new immune 
agents and other therapies that could change patient 
outcomes. In future, evaluations of treatment options 
and their associated outcomes can be conducted as part 
of Pathways- Bowel to determine both the therapeutic 
effectiveness and cost- effectiveness of existing and novel 
therapies as evidence becomes available in Australia.
survivorship
With 70% 5- year overall survival (2010–2014) and declines 
in mortality predicted to continue,12 survivorship issues 
are growing in relevance and importance. Most evidence 
is focused on patient surveillance for recurrence, with 
differences across available guidelines on the frequency 
and timing of follow- up tests.51 Survivorship issues include 
physical, psychological and social challenges, as well as 
ongoing healthcare needs.51–54 Australian evidence has 
suggested care is highly variable in CRC survivors and 
disparities by socioeconomic group are apparent.53 Amer-
ican guidelines for CRC survivorship have highlighted 
the role of risk- based healthcare, and there has been a 
shift in focus to improving patient outcomes through 
survivorship care plans and coordinated care.51 52 Evalu-
ations of survivorship issues and related interventions to 
improve outcomes will be integrated into future versions 
of Pathways- Bowel.
PrElIMInAry rEsults
This programme formalises an existing ongoing body 
of research which has already produced outputs. 
Work initially focused on evaluating the NBCSP 
using both predictive modelling and epidemiological 
research.15 20 21 37 41 An evaluation of NBCSP effective-
ness and cost- effectiveness at various participation 
levels showed that increasing participation from 40% 
to 60% would prevent 83 800 deaths from 2015 to 2040 
and reduce annual expenditure on CRC control within 
a decade of full NBCSP roll- out.15 We also explored the 
impact of optimistic NBCSP adherence rates, possibly 
beyond those achievable in practice, to determine 
whether the impact of such an intervention is substan-
tial and worth pursuing further.55
Alternative screening methods using different NBCSP 
screening modalities or different screening age groups 
have also been evaluated.20 21 The alternative technol-
ogies evaluated were plasma DNA testing, faecal DNA 
testing, CT colonography, flexible sigmoidoscopy and 
colonoscopy.21 Extensions to the target age range for 
the general population included extending to people 
in their 40s and/or people in their 80s.20 Considering 
the health outcomes and cost- effectiveness, the studies 
concluded that the planned NBCSP using biennial 
iFOBT and targeting people aged 50–74 years is currently 
the best option for CRC screening in Australia, and 
achieving higher screening participation within that age 
range can save more lives and improve the long- term 
cost- effectiveness.20 21 These results had a direct impact 
on clinical practice and policy as they were used to inform 
the 2017 ‘Clinical practice guidelines for the prevention, early 
detection and management of colorectal cancer’, approved by 
the National Health and Medical Research Council, and 
guided recommendations for the NBCSP.29
In addition to the planned modelled evaluations, epide-
miological data will also be assessed to quantify and char-
acterise screening occurring outside the NBCSP, which 
is thought to be considerable and may impact estimates 
of the benefits of increasing participation in NBCSP.56 
Further work has been undertaken and continues to 
inform guidelines and policy in areas of CRC manage-
ment, such as the updated national surveillance colonos-
copy guidelines.34 As additional evidence accumulates for 
potential interventions, these will be explored in future 
modelled evaluations and used to inform guidelines 
and policy change discussions. Notably, the Policy1- Bowel 
platform was used to evaluate a recent pilot mass media 
campaign aimed at increasing NBCSP participation; its 
results prompted a $10 million government investment in 
a national mass media campaign.43 This provides a clear 
demonstration on the usefulness of Pathways- Bowel in 
guiding investment and policy implementation.41–43
dIsCussIon
The proven ability and future capacity of the Pathways 
programme to identify the best- value investments in 
cancer control is critical in public health decision making. 
Pathways is a way to assess the impact of many more inter-
ventions than could be subject to clinical trials; the inter-
ventions can even be complementary, provided they are 
anchored in the real world. Internationally it has been 
recognised that demonstrating the cost- effectiveness of 
public health interventions helps to underpin commit-
ment from policymakers and funders.57 However, the 
varying methods by which interventions are evaluated 
make them difficult to compare and subject to method-
ological confounding.57
Pathways- Bowel is a unique, evidence- based, compre-
hensive approach to CRC control initially focused on 
screening interventions and their effectiveness in relation 
to the evolving knowledge of the natural history of CRC. 
There is relevant evidence in CRC, but no prior body of 
work has assessed the relative benefits of interventions 
across the CRC spectrum in a systematic way using a 
health economics framework and producing ‘best buys’ 
for the nation. By providing uniformly obtained, high- 
quality evidence guided by a standardised framework, 
which is in development, Pathways- Bowel has the capacity 
to drive CRC control change and improve outcomes for 
Australians across the entire spectrum of risk.
Pathways- Bowel engages and involves researchers, 
clinicians, consumers, policymakers and other key stake-
holders from its outset and throughout the process. 
Findings are presented so stakeholders can use the 
information to guide policy change priorities, funding 
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recommendations and decisions, and evidence- based 
advocacy for improved outcomes. Early results are inte-
grated with policy and advocacy efforts through local 
independent cancer control agencies with a track record 
in changing policy. The findings may also identify areas 
where further research could facilitate evaluations and 
guide research priority setting by funders.
The predictive modelling used in the Pathways 
programme is not without its limitations. It is dependent 
on the available data sources and assumptions made in 
the absence of robust data. In Australia we are fortunate 
to have high- quality data available on CRC incidence and 
mortality and regular monitoring reports made publicly 
available on the performance of the NBCSP. These data 
have been used to develop a robust and sound Policy1- 
Bowel platform. Nevertheless, the modelled results remain 
predictions. It is through extensive validation with trial 
outcomes, continual improvement of the model and 
input of updated real- world observational information as 
it becomes available that the outputs are strengthened.
In terms of health economics, the health services 
perspective used limits the interpretation of results. 
Economic modelling, by itself, does not explicitly aid poli-
cymakers to maximise equity. However, more broadly, the 
Pathways- Bowel programme of research embeds equity as 
a pillar. Through Pathways, standard economic analyses 
are complemented by systematic predictive modelling 
for specific groups and issues. Although applicable to the 
Australian general population, the outcomes can be eval-
uated for other contexts where data are available. Aborig-
inal and Torres Strait Islander peoples, for example, have 
seen varying trends in CRC incidence and mortality over 
time when compared with the Australian population, with 
significant increase in incidence, no statistically signifi-
cant trend in mortality and a lower 5- year relative survival 
(58%).58 Evaluations have been done for this population 
group to assess the impact of NBCSP screening from ages 
40 to 74, and modelling of subgroups can be extended to 
culturally and linguistically diverse populations living in 
Australia as required. Overall, the flexibility of the model-
ling platform used in Pathways- Bowel allows for its appli-
cation to other settings in the future, both for developed 
and developing countries, and this has already begun for 
China.
While the current focus is on prevention and screening, 
Pathways- Bowel and the Policy1- Bowel platform have the 
flexibility to evaluate diagnosis, treatment and survivor-
ship interventions as evidence is gathered. The capacity 
of the model is continually being extended and strength-
ened with each new modelled evaluation performed. 
There is much promise in current research to identify 
optimal approaches to population- based screening for 
CRC in Australia. The Pathways programme has already 
been established based on a comprehensive analysis 
of the associated benefits, harms and costs. The next 
step, implementation of interventions and policies into 
practice, is crucial for ensuring the benefits of optimal 
approaches are realised by the Australian population, and 
has begun for patients with Lynch syndrome.18 Evidence- 
based approaches to inform ‘best buys’ in policy reform, 
accounting for context, system complexity and stake-
holder perspectives, are a fundamental prerequisite for 
successful and sustained translation of discoveries into 
real- world settings. The Pathways programme presents 
the opportunity to continually optimise evidence- based 
support for cancer control interventions.
EthICs And dIssEMInAtIon
The Pathways- Bowel protocol for modelled evaluations 
has been reviewed and approved by the SAC. No human 
participants are involved to perform modelled evalua-
tions and therefore human research ethics committee 
was not required. Where epidemiological analyses are 
planned and require ethics approval, it will be sought. No 
deviations from the protocol will be made without prior 
review and approval of the relevant working party leads 
from the SAC.
study status
Pathways- Bowel officially commenced in early 2017 and 
is an ongoing collaboration with the SAC and other CRC 
specialist researchers. As results become available, they 
are reviewed and prepared for peer- reviewed publication. 
The status is outlined in table 1. The expected comple-
tion date for the currently outlined evaluations is 2023.
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